Saludos, quisiera saber si tienen reportes o datos de sintomatología actual por infección por COVID.

Ya que he valorado pacientes con mínimos síntomas respiratorios, asociados a fiebre elevada y ocasionalmente conjuntivitis, desconozco si ha habido actualización de síntomas por que la variante Arcturus generaba cuadros de conjuntivitis severa. 

Espero tenga alguien información al respecto que puedan compartir. 

A study published in the journal Vaccine evaluated the effects of a booster dose of BNT162b2 (Pfizer-BioNTech) vaccine on spike-binding antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals

I am honestly looking for fellow and female physicians' opinions. It is too easy to offend. I will preface: "It is easy to rush to negative criticism".

My understanding + experience:

1. COVID (and variants) with IP 5-15 days: multiply/replicate in the NOSE, frequently for 4-5 days before spreading.

2. COVID has a multi-protein capsule (MNE and S) which can be destroyed by SLS (sodium lauryl ether sulfate).

3. SLS was introduced in about 1902 into soaps to make bubbles.

4. SLS is now present in soaps, shampoo, body wash, toothpaste, mouthwash, and even shaving cream  (At a different concentration in detergent. It was known to kill "organisms").

5. QUESTION:  Does it make sense, if early COVID is suspected: after emptying the nose, and washing hands: place a soapy finger up each nostril? (Then rinse).

6. QUESTION: If the COVID basecamp is in the nose, and SLS kills COVID, does it not make sense to bring the bubbles into contact for COVID annihilation?

7. At least one published study concluded a 95% kill rate of COVID using SLS.

8. I do not have a prospective, randomized, double-blind study of 50,000 covid cases.

9. But as an 85-year OBGYN, I have worked with pregnant (and other) COVID patients for 2 years using soapy shampoo, regular soap, mouthwash, and encouraging baths (twice daily) with body wash: bringing bubbles in contact with the interior nostril.   I used it as a personal preventive. I recommended it to my staff. It is an extra tool, not a substitute for anti-virals, vaccines, etc.

10. I found fast improvement. And no nasal excoriation.

11. I suspect a factor in the high death rate among homeless and nursing home patients, is, if fortunate, a bed bath only.

THANK YOU for your opinions from your experience.

American Academy of Family Physicians American College of Obstetricians and Gynecologists American College of Physicians American College of Cardiology American College of Surgeons American College of Allergy, Asthma & Immunology

Dr Robert Gottlieb, Dr Roger Paredes and Prof. Elizabeth Sapey look at data assessing:

• Effectiveness of remdesivir across different SARS-CoV-2 variant eras

• Remdesivir in immunocompromised patients

• Remdesivir’s impact on hospital readmissions

Click here for GB prescribing information

Click here for NI/I prescribing information

AE reporting below

Hear from global experts on COVID-19 discuss VEKLURY®▼(remdesivir) real world evidence:

• Remdesivir reduced mortality vs matched controls in patients hospitalised 

  with COVID-19 across variant eras1

• Remdesivir reduced mortality vs matched controls in 

  immunocompromiseda patients hospitalised with COVID-192

• Remdesivir reduced readmissions vs controls in hospitalised patients with 

  COVID-193

These findings are from large retrospective studies using the PINC AI healthcare database.

The safety profile and efficacy of remdesivir in immunocompromised patients have not yet been established. Only limited data are available.

The most common adverse reactions associated with remdesivir are nausea, increased transaminases and prolonged prothrombin time.4

a Cancer, solid organ and haematopoietic stem cell transplant, haematologic malignancies, primary immunodeficiencies, asplenia, bone marrow failure/aplastic anaemia, severe combined immunodeficiencies or HIV.

To view more information about management of COVID-19, visit hosted.bmj.com/gilead/conversations-on-covid

▼Additional monitoring required.

Adverse Events should be reported. For the United Kingdom, reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store). For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500.

Intended for healthcare professionals only.

Developed and funded by Gilead Sciences Europe Ltd.

Job code IHQ-RDV-0307, July 2023

References:

1. Mozaffari E, et al. CROI 2023, Poster 556. 

2. Mozaffari E, et al. CROI 2023, Poster 557. 

3. Mozaffari E, et al. CROI 2023, Poster 558. 

4. VEKLURY (remdesivir) SmPC.   

British Columbia is preparing for a fall rollout of an updated COVID-19 vaccine, tailored specifically to the Omicron variant. Provincial health officer Dr. Bonnie Henry emphasized that the new vaccine should be seen as an annual immunization similar to the flu shot, rather than just a booster dose. The recommendation from the National Advisory Committee on Immunization (NACI) suggests that Canadians should receive the updated vaccine if it has been six months since their last dose or COVID-19 infection. The aim is to provide protection against the strains circulating in Canada and globally, building upon the immunity gained from previous vaccinations. The province plans to make the vaccination process easy and convenient, and anyone who wants the vaccine will be offered it. With the anticipation of a potential fall surge of the virus, health officials are urging the public to stay informed and take advantage of this updated vaccine to help combat COVID-19 and ensure community protection...Read More

What are your thoughts?

MONDAY, July 10, 2023 (HealthDay News) -- High levels of genetically proxied appendicular lean mass are associated with reduction in the risk of Alzheimer disease, according to a study published online June 29 in BMJ Medicine.

Iyas Daghlas, M.D., from the University of California San Francisco, and colleagues conducted a Mendelian randomization study to examine whether genetically proxied lean mass is associated with Alzheimer disease. Summary level genetic data were included from 450,243 U.K. Biobank participants; an independent sample of 21,982 patients with and 41,944 controls without Alzheimer disease; a replication sample of 7,329 patients with Alzheimer disease and 252,879 controls; and 269,867 individuals participating in a genome-wide association study of cognitive performance.

The researchers found that a 1 standard deviation increase in genetically proxied appendicular lean mass was associated with a reduction in Alzheimer disease risk (odds ratio [OR], 0.88). This finding was replicated in an independent cohort of Alzheimer disease patients (OR, 0.91) and was consistent in sensitivity analyses more robust to inclusion of pleiotropic variants. Higher genetically proxied appendicular lean mass was also associated with increased cognitive performance (standard deviation increase in cognitive performance for each standard deviation increase in appendicular lean mass, 0.09). The association between appendicular lean mass and risk of Alzheimer disease was not reduced after adjustment for potential mediation through genetically proxied cognitive performance.

"We identified genetic support for a protective effect of lean mass on the risk of Alzheimer's disease and on higher cognitive performance," the authors write. "Further investigation is warranted to understand the clinical and public health implications of these findings."

One author disclosed ties to Novo Nordisk.

Abstract/Full Text

Copyright © 2020 HealthDay. All rights reserved.